MARCHF2 and viral infectious disease: Virus infection experiments indicated that, at 120 h post-infection, MARCH2 neither degraded gp85 nor suppressed viral replication in the K282R mutant ALV-B (Fig. 7H through J) and ALV-J (Fig. 7K through M).